American Journal of Ethnomedicine

Analgesic, anti-inflammatory and anticancer activities of Combretin A and Combretin B isolated from Combretum fragrans F. Hoffm (Combretaceae) leaves

6^th Edition of International Conference on Pharmacognosy and Medicinal Plants
April 16-17, 2018 Amsterdam, Netherlands

Mbiantcha Marius, Almas jabeen, Dawe Amadou, Faheem Aisha and Sidra Zafar

Dschang, Cameroon

Posters & Accepted Abstracts: Am J Ethnomed

DOI: 10.21767/2348-9502-C1-006

Abstract

Pharmacological and phytochemical research shows that Combretum fragrans F. Hoffm (Combretaceae) is a plant possessing numerous therapeutic virtues and rich in active secondary compounds. In this study, we investigate the in vivo (antinociceptive, anti-inflammatory) and in vitro (anti-cancer, anti-TNFα, ROS and NO inhibitor) capacity of Combretin A and Combretin B, the triterpenes (cycloartane-type) isolated from Combretum fragrans. ROS production from phagocytes, TNF-α production, NO production, anticancer and cytotoxicity assay were done by using chemiluminescence technique, ELISA kit, colorimetric method, MCF-7 Cells and MTT assay, respectively. Antinociceptive and anti-inflammatory activity was estimated using a model of acetic acid, formalin and carrageenan. Combretin A and Combretin B significantly (p<0.001) inhibited extracellular ROS production. These compounds also possess significant (p<0.001) reduced TNF-α and NO production. The compound decreased cell viability in MCF-7 cells. Concerning the pain induced by acetic acid and formalin as acute inflammation in rat induced by carrageenan, Combretin A and Combretin B exhibited significantly (p<0.001) antinociceptive and anti-inflammatory activity. Antinociceptive, anti-inflammatory and anticancer potential associated with inhibitors effect on ROS, TNFα and NO production revealed in this study approve that, Combretin A and Combretin B are considered as a promising chemotherapeutic agent in breast cancer treatment and inflammatory disease.

Biography

E-mail: